Despite the growing ubiquity of data in the medical domain, it remains difficult to apply results from experimental and observational studies to additional populations suffering from the same disease. Many methods are employed for testing internal validity; yet limited effort is made in testing generalizability, or external validity. The development of disease models often suffers from this lack of validity testing and trained models frequently have worse performance on different populations, rendering them ineffective. In this work, we discuss the use of transportability theory, a causal graphical model examination, as a mechanism for determining what elements of a data resource can be shared or moved between a source and target population. A simplified Bayesian model of glioblastoma multiforme serves as the example for discussion and preliminary analysis. Examination over data collection hospitals from the TCGA dataset demonstrated improvement of prediction in a transported model over a baseline model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419978 | PMC |
Alzheimers Dement
December 2024
Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Autonomous University of Barcelona, Barcelona, Catalonia, Spain.
Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Central South University, Changsha, Hunan, China.
Background: This prediction model quantifies the risk of cognitive impairment. This aim of this study was to develop and validate a prediction model to calculate the 6-year risk of cognitive impairment.
Methods: Participants from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) 2008-2014 and 2011-2018 surveys were included for developing the cognitive impairment prediction model.
Alzheimers Dement
December 2024
North Bristol NHS Trust, Bristol, United Kingdom.
Background: Poor sleep is associated with neurodegenerative diseases underlying dementia and mild cognitive impairment (MCI), including Alzheimer's disease (AD) and Lewy body disease (LBD). Performing assessments within clinical or laboratory settings may influence validity, however feasibility of home sleep and memory assessments in this population is currently undetermined. This study aimed to identify whether remote home-based sleep and memory research including wearable technology was feasible in older adults with MCI and dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Erasmus University Rotterdam, Rotterdam, Netherlands.
Background: 'Intellectual assets' generated in traditional university settings, that may not fit the interests of the standard 'valuation criteria' (i.e. commercially profitable), such as non-pharmacological dementia care research, often remain siloed within their respective research disciplines and originating institutions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!